Science from the Dan Barouch Lab at @BIDMCHealth and @harvardmed’s Center for Virology & Vaccine Research. RTs ≠ endorsements
Boston, MA
Joined July 2020
- Tweets408
- Following229
- Followers1.5K
- Likes1.9K
Pinned Tweet
New data from the Barouch Lab on BA.2.86.
1. NAb responses to BA.2.86 were lower than to BA.2 but were comparable or higher than to current circulating variants.
2. NAb titers to all variants including BA.2.86 increased following XBB infection
Barouch Lab retweeted
Long COVID involves activation of proinflammatory and immune exhaustion pathways @NatImmunol @BarouchLab
nature.com/articles/s41590-0…
Barouch Lab retweeted
Vaccines for #H5N1 based on either mRNA or an adenovirus vector can shield macaques from the virus when delivered via an intramuscular prime and a mucosal boost regimen, according to new experiments. @lasradoN @BarouchLab @BIDMC_CVVRTrial scim.ag/3KUJqll
Barouch Lab retweeted
Vaccines for #H5N1 based on either mRNA or an adenovirus vector can shield macaques from the virus when delivered via an intramuscular prime and a mucosal boost regimen, according to new experiments. @lasradoN @BarouchLab @BIDMC_CVVRTrial scim.ag/3KUJqll
Barouch Lab retweeted
Excited to share our work on mucosal vaccines against HPAI #H5N1 @ScienceTM @BarouchLab!! We show how mRNA and adenovirus vaccines provide protection against H5N1, with mucosal adenovirus delivery providing near complete protection!
science.org/doi/10.1126/scit…
Barouch Lab retweeted
Was informed @BarouchLab is still actively recruiting participants in the New England area--
#LongCovid
*Not to be used as medical advice or diagnosis. ILCA does not endorse any trial or sponsor.
Barouch Lab retweeted
Mucosal delivery of a rhesus adenovirus–vectored H5N1 influenza vaccine confers protection against lethal challenge in cynomolgus macaques
science.org/doi/10.1126/scit… @ScienceTM @lasradoN @BarouchLab @harvardmed 🇺🇸
Barouch Lab retweeted
Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)
Barouch Lab retweeted
Published today in @CellCellPress: A new mRNA #TB vaccine developed at @BIDMChealth’s CVVR by @BarouchLab protected mice better than the century-old BCG shot — reducing infection, slowing spread & lowering lung bacterial levels. 🧬💉 dlvr.it/TN5Lmp
Barouch Lab retweeted
Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines @BarouchLab @CellCellPress @BIDMChealth @harvardmed 🇺🇸
cell.com/cell/fulltext/S0092…
Barouch Lab retweeted
Beautiful paper from @BarouchLab looking at H5N1 pathogenesis in rhesus & cynomolgus macaques (link in replies).
Dan presented some of this work in Feb at a meeting at Scripps & the mortality data was striking. H5N1 is really pathogenic in macaques, but in species-specific ways.
Barouch Lab retweeted
Mucosal delivery and gene-based vaccines can both enhance boost responses for influenza vaccination in cynomolgus macaques over available vaccines
science.org/doi/10.1126/scit…
@ScienceTM @BarouchLab
Barouch Lab retweeted
mRNA or adenovirus flu vaccine boosters produce strong immune responses against H1N1 and match the efficacy of a live-attenuated booster in macaques, supporting their potential as a more flexible platform for #influenza vaccines. @BarouchLab @BIDMChealth scim.ag/45Zjb5M
Barouch Lab retweeted
#LongCovid has impaired millions of people, with no cure on the horizon. @BIDMC_CVVRTrial has launched a trial to test Abrocitinib to alleviate LC symptoms. If you’re around Boston, see if you qualify! 👇@thephysicsgirl
@ImmunoFever @EricTopol @VirusesImmunity @LCCampaign
Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)
Email [email protected] or call 617-735-4610 to inquire. Additional information can also be found here [clinicaltrials.gov/study/NCT…]. (2/2)
Barouch Lab retweeted
I'm very excited to share our recent paper describing the antigenic relationship of SARS-CoV-2 variants in Nonhuman primates for the first time.
@BarouchLab @annetzl @lasradoN @JanineKimpel @Cambridge_Uni @MedUniInnsbruck
cell.com/cell-reports/fullte…
Barouch Lab retweeted
It took some time for this to come out, but I am glad it's out now @ScienceTM!!! It was a huge effort by our team @BarouchLab @airisyc @CamilleRMazurek and many more to evaluate mucosal immune responses, 4 years into the COVID-19 pandemic.
science.org/doi/10.1126/scit…
Barouch Lab retweeted
This study shows that mpox antibody responses generated by the MVA-BN vaccine wane significantly within 6 to 12 months, potentially leaving individuals vulnerable to reinfection.
ja.ma/47UtpTG
Barouch Lab retweeted
New data from @BIDMChealth @BarouchLab suggests that protective immunity against #Mpox may have waned in previously vaccinated individuals and that boosting may be required to maintain robust protection
This study shows that mpox antibody responses generated by the MVA-BN vaccine wane significantly within 6 to 12 months, potentially leaving individuals vulnerable to reinfection.
ja.ma/47UtpTG
Barouch Lab retweeted
Ahead of #HIVVaccineAwarenessDay JIAS has published a new viewpoint, “The potential of broadly neutralizing antibodies for HIV prevention”.
Read it here: bit.ly/4bHHTHj #HVAD
@huubgelderblom @BarouchLab
